Anticoagulation: Low-Molecular-Weight Heparins in Renal Impairment and Obesity: Available Evidence and Clinical Practice Recommendations Across Medical and Surgical Settings

Abstract

Spanish

French

Objective

To develop practical recommendations for the use of low-molecular-weight heparins (LMWHs) as prophylaxis and treatment of venous thromboembolism and acute coronary syndromes in patients with impaired renal function or obesity.

Data Sources

Multiple MEDLINE searches were performed (November 2008) to identify studies for inclusion, using a comprehensive list of search terms including, but not limited to, LMWH, enoxaparin, dalteparin, tinzaparin, obesity, weight, renal, kidney, elderly, monitoring, and anti-Xa.

Study Selection And Data Extraction

Only articles published in English that were relevant for this review were included.

Data Synthesis

In the majority of patients, standardized prophylaxis or treatment doses of LMWHs can be used without the need for monitoring and adjusting regimens. For patients with severe renal impairment (estimated creatinine clearance [CrCl] <30 mL/min), doses of some LMWHs should be adjusted or unfractionated heparin should be used instead. CrCl should be estimated using the Cockcroft-Gault method. Differences are noted in the degree of accumulation of various LMWHs in patients with moderate-to-severe renal impairment, and thus, the degree of dose adjustment may differ among the various LMWHs. Increasing the prophylactic doses of LMWH may be appropriate in morbidly obese patients (body mass index ≥40 kg/m²). The use of total body weight is appropriate for therapeutic doses of LMWH in obese patients. Laboratory monitoring of the anticoagulation effect of LMWHs is generally not necessary, but should be considered in patients with morbid obesity (weight >190 kg), those with severe renal impairment, and those with moderate renal impairment with prolonged (>10 days) LMWH use. When anti-Xa activity is monitored, it should be determined using a chromogenic method and a calibration curve based on the LMWH used.

Conclusions

Additional data are needed for specific dose guiding in obese and renally impaired patients, who are often excluded from larger clinical trials. Practice recommendations are made based on available evidence and authors' clinical opinions.

Keywords

anti-Factor Xa activity chronic kidney disease dalteparin dosing enoxaparin low-molecular-weight heparin monitoring obesity practice recommendations renal impairment tinzaparin

Get full access to this article

View all access options for this article.

References

Montalescot

Collet

Tanguy

. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin. Circulation 2004;110:392–8.

Nutescu

Dager

. Heparin, low molecular weight heparin, and fondaparinux. In: Gulseth

Managing anticoagulation patients in the hospital. The inpatient anticoagulation service. Bethesda, MD: American Society of Health-System Pharmacists, 2007: 177–202.

Lim

Dentali

Eikelboom

Crowther

. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 2006;144:673–84.

Hull

Pineo

Francis

. Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: a double-blind, randomized comparison. The North American Fragmin Trial Investigators. Arch Intern Med 2000;160:2199–207.

Lee

Levine

Baker

. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146–53.

Leizorovicz

Cohen

Turpie

. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004;110:874–9.

Deitcher

Kessler

Merli

. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost 2006;12:389–96.

Samama

Cohen

Darmon

. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999;341:793–800.

Comp

Spiro

Friedman

. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. Enoxaparin Clinical Trial Group. J Bone Joint Surg Am 2001;83-A: 336–45.

10.

Merli

Spiro

Olsson

. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med 2001;134:191–202.

11.

Simonneau

Sors

Charbonnier

. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire. N Engl J Med 1997;337:663–9.

12.

Hull

Raskob

Brant

. Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. American-Canadian Thrombosis Study Group. Arch Intern Med 2000;160:229–36.

13.

Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group. Lancet 1996; 347: 561–8.

14.

Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease. Investigators. Lancet 1999; 354: 701–7.

15.

Klein

Buchwald

Hillis

. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC). Circulation 1997;96:61–8.

16.

Cohen

Demers

Gurfinkel

. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 1997;337:447–52.

17.

Antman

McCabe

Gurfinkel

. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non–Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) IIB trial. Circulation 1999;100:1593–601.

18.

Blazing

de Lemos

White

. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non–ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. JAMA 2004;292:55–64.

19.

Ferguson

Califf

Antman

. Enoxaparin vs unfractionated heparin in high-risk patients with non–ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004;292:45–54.

20.

Michalis

Katsouras

Papamichael

. Enoxaparin versus tinzaparin in non–ST-segment elevation acute coronary syndromes: the EVET trial. Am Heart J 2003;146:304–10.

21.

Antman

Morrow

McCabe

. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 2006;354:1477–88.

22.

Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001; 358: 605–13.

23.

Wallentin

Goldstein

Armstrong

. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. Circulation 2003;108:135–42.

24.

Spinier

Inverso

Cohen

. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. Am Heart J 2003;146:33–41.

25.

Levey

Coresh

Balk

. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003;139:137–47.

26.

Poggio

Wang

Greene

Van Lente

Hall

. Performance of the Modification of Diet in Renal Disease and Cockcroft-Gault equations in the estimation of GFR in health and in chronic kidney disease. J Am Soc Nephrol 2005;16:459–66.

27.

Stevens

Coresh

Greene

Levey

. Assessing kidney function—measured and estimated glomerular filtration rate. N Engl J Med 2006;354:2473–83.

28.

Fehrman-Ekholm

Skeppholm

. Renal function in the elderly (>70 years old) measured by means of iohexol clearance, serum creatinine, serum urea and estimated clearance. Scand J Urol Nephrol 2004;38:73–7.

29.

Swedko

Clark

Paramsothy

Akbari

. Serum creatinine is an inadequate screening test for renal failure in elderly patients. Arch Intern Med 2003;163:356–60.

30.

Antman

Hand

Armstrong

. 2007 Focused update of the ACC/AHA 2004 Guidelines for the Management of Patients with ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation 2008;117:296–329.

31.

Brophy

Martin

Gehr

Best

Paul

Carr

Jr. . Thrombin generation time is a novel parameter for monitoring enoxaparin therapy in patients with end-stage renal disease. J Thromb Haemost 2006;4:372–6.

32.

Bazinet

Almanric

Brunet

. Dosage of enoxaparin among obese and renal impairment patients. Thromb Res 2005;116:41–50.

33.

Sanderink

Guimart

Ozoux

Jariwala

Shukla

Boutouyrie

. Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment. Thromb Res 2002;105:225–31.

34.

Mahé

Gouin-Thibault

Drouet

. Elderly medical patients treated with prophylactic dosages of enoxaparin: influence of renal function on anti-Xa activity level. Drugs Aging 2007;24:63–71.

35.

Mahé

Aghassarian

Drouet

. Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function: a comparative pharmacokinetic study. Thromb Haemost 2007;97:581–6.

36.

Tincani

Mannucci

Casolari

. Safety of dalteparin for the prophylaxis of venous thromboembolism in elderly medical patients with renal insufficiency: a pilot study. Haematologica 2006;91:976–9.

37.

Rabbat

Cook

Crowther

. Dalteparin thromboprophylaxis for critically ill medical-surgical patients with renal insufficiency. J Crit Care 2005;20:357–63.

38.

Schmid

Brodmann

Fischer

Wuillemin

. Pharmacokinetics of dalteparin in prophylactic dosage in patient with impaired renal function (abstract). J Thromb Haemost 2007;5(suppl 2):P-T-674.

39.

Douketis

Cook

Meade

; Canadian Critical Care Trials Group. Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study. Arch Intern Med. 2008;168:1805–12.

40.

Shprecher

Cheng-Lai

Madsen

. Peak antifactor Xa activity produced by dalteparin treatment in patients with renal impairment compared with controls. Pharmacotherapy 2005;25:817–22.

41.

Product information. Lovenox (enoxaparin sodium injection). Bridgewater, NJ: sanofi-aventis US LLC, May 2007.

42.

Becker

Spencer

Gibson

. Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non–ST-segment elevation acute coronary syndromes. Am Heart J 2002;143:753–9.

43.

Bruno

Baille

Retout

. Population pharmacokinetics and pharmacodynamics of enoxaparin in unstable angina and non–ST-segment elevation myocardial infarction. Br J Clin Pharmacol 2003;56:407–14.

44.

Hulot

Montalescot

Lechat

Collet

Ankri

Urien

. Dosing strategy in patients with renal failure receiving enoxaparin for the treatment of non–ST-segment elevation acute coronary syndrome. Clin Pharmacol Ther 2005;77:542–52.

45.

Chow

Zammit

West

Dannenhoffer

Lopez-Candales

. Correlation of antifactor Xa concentrations with renal function in patients on enoxaparin. J Clin Pharmacol 2003;43:586–90.

46.

Pautas

Gouin

Bellot

Andreux

Siguret

. Safety profile of tinzaparin administered once daily at a standard curative dose in two hundred very elderly patients. Drug Saf 2002;25:725–33.

47.

Siguret

Pautas

Février

. Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 days. Thromb Haemost 2000;84:800–4.

48.

Barrett

Gibiansky

Hull

. Population pharmacodynamics in patients receiving tinzaparin for the prevention and treatment of deep vein thrombosis. Int J Clin Pharmacol Ther 2001;39:431–46.

49.

Thorevska

Amoateng-Adjepong

Sabahi

. Anticoagulation in hospitalized patients with renal insufficiency: a comparison of bleeding rates with unfractionated heparin vs enoxaparin. Chest 2004;125:856–63.

50.

Collet

Montalescot

Fine

. Enoxaparin in unstable angina patients who would have been excluded from randomized pivotal trials. J Am Coll Cardiol 2003;41:8–14.

51.

Collet

Montalescot

Agnelli

. Non–ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events. Eur Heart J 2005;26:2285–93.

52.

Fox

Amman

Montalescot

. The impact of renal dysfunction on outcomes in the ExTRACT-TIMI 25 trial. J Am Coll Cardiol 2007;49:2249–55.

53.

Fox

Bassand

Mehta

. Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes. Ann Intern Med 2007;147:304–10.

54.

Polkinghorne

McMahon

Becker

. Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients. Am J Kidney Dis 2002;40:990–5.

55.

Falgá

Capdevila

Soler

. Clinical outcome of patients with venous thromboembolism and renal insufficiency. Findings from the RIETE registry. Thromb Haemost 2007;98:771–6.

56.

Schrier

. Cardiorenal versus renocardiac syndrome: is there a difference? Nat Clin Pract Nephrol 2007;3:637.

57.

Dries

Exner

Domanski

Greenberg

Stevenson

. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2000;35:681–9.

58.

Cohen

Alexander

Rao

. Bleeding after antithrombotic therapy in patients with acute ischemic heart disease: is it the drugs or how we use them? J Thromb Thrombolysis 2008;26:175–82. Epub 15 Dec 2007. DOI 10.1007/s11239-007-0182-x

59.

Warkentin

Crowther

. Reversing anticoagulants both old and new. Can J Anaesth 2002;49(suppl):S11–25.

60.

Lachish

Rudensky

Slotki

Zevin

. Enoxaparin dosage adjustment in patients with severe renal failure: antifactor Xa concentrations and safety. Pharmacotherapy 2007;27:1347–52.

61.

Kruse

Lee

. Retrospective evaluation of a pharmacokinetic program for adjusting enoxaparin in renal impairment. Am Heart J 2004;148:582–9.

62.

Green

Greenwood

Saltissi

. Dosing strategy for enoxaparin in patients with renal impairment presenting with acute coronary syndromes. Br J Clin Pharmacol 2005;59:281–90.

63.

Hsu

Vittinghoff

Lin

Shlipak

. The incidence of end-stage renal disease is increasing faster than the prevalence of chronic renal insufficiency. Ann Intern Med 2004;141:95–101.

64.

Berges

Laporte

Epinat

. Anti-factor Xa activity of enoxaparin administered at prophylactic dosage to patients over 75 years old. Br J Clin Pharmacol 2007;64:428–38.

65.

White

Braunwald

Murphy

. Enoxaparin vs. unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction in elderly and younger patients: results from ExTRACT-TIMI 25. Eur Heart J 2007;28:1066–71.

66.

Lim

Cook

Crowther

. Safety and efficacy of low molecular weight heparins for hemodialysis in patients with end-stage renal failure: a meta-analysis of randomized trials. J Am Soc Nephrol 2004;15:3192–206.

67.

Isla

Gascón

Maynar

. In vitro and in vivo evaluation of enoxaparin removal by continuous renal replacement therapies with acrylonitrile and polysulfone membranes. Clin Ther 2005;27:1444–51.

68.

Duplaga

Rivers

Nutescu

. Dosing and monitoring of low-molecular-weight heparins in special populations. Pharmacotherapy 2001;21:218–34.

69.

Spinier

Fang-Shu

Roe

Gibler

Ohman

Peterson

. Enoxaparin dosing in obese patients with non–ST-segment elevation acute coronary syndrome (NSTE ACS): results from CRUSADE. Pharmacotherapy 2006;26: e56–7.

70.

Spinier

Dobesh

. Dose capping enoxaparin is unjustified and denies patients with acute coronary syndromes a potentially effective treatment. Chest 2005;127:2288–9.

71.

Spinier

. The skinny on treatment of venous thromboembolism in obesity. J Thromb Haemost 2005;3:854–5.

72.

Wilson

Wilbur

Burton

Anderson

. Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low-molecular-weight heparin for the treatment of venous thromboembolism. Haemostasis 2001;31:42–8.

73.

Samama

Verhille

Carchy

. Relation between weight, obesity, and frequency of deep vein thrombosis after enoxaparin in orthopedic surgery (abstract 300). Thromb Haemost 1995;73:977.

74.

Frederiksen

Hedenbro

Norgren

. Enoxaparin effect depends on body-weight and current doses may be inadequate in obese patients. Br J Surg 2003;90:547–8.

75.

Simone

Madan

Tichansky

Kuhl

Lee

. Comparison of two low-molecular-weight heparin dosing regimens for patients undergoing laparoscopic bariatric surgery. Surg Endosc 2008;22:2392–5.

76.

Borkgren-Okonek

Hart

Pantano

. Enoxaparin thromboprophylaxis in gastric bypass patients: extended duration, dose stratification, and antifactor Xa activity. Surg Obes Relat Dis 2008;4:625–31.

77.

Kucher

Leizorovicz

Vaitkus

. Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial. Arch Intern Med 2005;165:341–5.

78.

Scholten

Hoedema

Scholten

. A comparison of two different prophylactic dose regimens of low molecular weight heparin in bariatric surgery. Obes Surg 2002;12:19–24.

79.

Escalante-Tattersfield

Tucker

Fajnwaks

Szomstein

Rosenthal

. Incidence of deep vein thrombosis in morbidly obese patients undergoing laparoscopic Roux-en-Y gastric bypass. Surg Obes Relat Dis 2008;4:126–30.

80.

Kardys

Stoner

Manwaring

. Safety and efficacy of intravascular ultrasound-guided inferior vena cava filter in super obese bariatric patients. Surg Obes Relat Dis 2008;4:50–4.

81.

Hamad

Choban

. Enoxaparin for thromboprophylaxis in morbidly obese patients undergoing bariatric surgery: findings of the prophylaxis against VTE outcomes in bariatric surgery patients receiving enoxaparin (PROBE) study. Obes Surg 2005;15:1368–74.

82.

Frydman

. Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. Haemostasis 1996;26(suppl 2):24–38.

83.

Andrassy

Eschenfelder

. Are the pharmacokinetic parameters of low molecular weight heparins predictive of their clinical efficacy? Thromb Res 1996;81(suppl 2):S29–38.

84.

Smith

Canton

. Weight-based administration of dalteparin in obese patients. Am J Health Syst Pharm 2003;60:683–7.

85.

Yee

Duffull

. The effect of body weight on dalteparin pharmacokinetics. A preliminary study. Eur J Clin Pharmacol 2000;56:293–7.

86.

Sanderink

Liboux

Jariwala

. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin Pharmacol Ther 2002;72:308–18.

87.

Hainer

Barrett

Assaid

. Dosing in heavy-weight/obese patients with the LMWH tinzaparin: a pharmacodynamic study. Thromb Haemost 2002;87:817–23.

88.

Al-Yaseen

Wells

Anderson

Martin

Kovacs

. The safety of dosing dalteparin based on actual body weight for the treatment of acute venous thromboembolism in obese patients. J Thromb Haemost 2005;3:100–2.

89.

Barba

Marco

Martín-Alvarez

. The influence of extreme body weight on clinical outcome of patients with venous thromboembolism: findings from a prospective registry (RIETE). J Thromb Haemost 2005;3:856–62.

90.

Macie

Forbes

Foster

Douketis

. Dosing practices and risk factors for bleeding in patients receiving enoxaparin for the treatment of an acute coronary syndrome. Chest 2004;125:1616–21.

91.

Anderson

Adams

Antman

. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non–ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007;50: e1–e157.

92.

Product information. Fragmin (dalteparin sodium injection). New York, NY: Pfizer Inc., April 2007.

93.

Jackevicius

Yeo

. Anti-Xa monitoring of enoxaparin for acute coronary syndromes in patients with renal disease. Ann Pharmacother 2004;38:1576–81. Epub 24 Aug 2004. DOI 10.1345/aph.1E096

94.

Laposata

Green

Van Cott

Barrowcliffe

Goodnight

Sosolik

. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: the clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban. Arch Pathol Lab Med 1998;122:799–807.

95.

Kearon

Kahn

Agnelli

Goldhaber

Raskob

Comerota

. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 8th ed. Chest 2008;133: 454S–545S.

96.

Rowan

McLintock

Taylor

North

. Prophylactic and therapeutic enoxaparin during pregnancy: indications, outcomes and monitoring. Aust N Z J Obstet Gynaecol 2003;43:123–8.

97.

El Rouby

Cohen

Gonzales

. The use of a HEMOCHRON JR. HEMONOX point of care test in monitoring the anticoagulant effects of enoxaparin during interventional coronary procedures. J Thromb Thrombolysis 2006;21:137–45.

98.

Díez

Cheong

O'meallie

Alt

. Monitoring of enoxaparin level using citrated clotting time during percutaneous coronary intervention. J Interv Cardiol 2004;17:307–13.

99.

Nieuwenhuis

Albada

Banga

Sixma

. Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin. Blood 1991;78:2337–43.

100.

Bara

Planes

Samama

. Occurrence of thrombosis and haemorrhage, relationship with anti-Xa, anti-IIa activities, and d-dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery. Br J Haematol 1999;104:230–40.

101.

Favaloro

Bonar

Aboud

. How useful is the monitoring of (low molecular weight) heparin therapy by anti-Xa assay? A laboratory perspective. Lab Hematol 2005;11:157–62.

102.

Boneu

Bes

Pelzer

Sié

Boccalon

. d-Dimers, thrombin antithrombin III complexes and prothrombin fragments 1+2: diagnostic value in clinically suspected deep vein thrombosis. Thromb Haemost 1991;65:28–31.

103.

Kitchen

Iampietro

Woolley

Preston

. Anti Xa monitoring during treatment with low molecular weight heparin or danaparoid: inter-assay variability. Thromb Haemost 1999;82:1289–93.

104.

Samama

Poller

. Contemporary laboratory monitoring of low molecular weight heparins. Clin Lab Med 1995;15:119–23.

105.

Kovacs

Keeney

MacKinnon

Boyle

. Three different chromogenic methods do not give equivalent anti-Xa levels for patients on therapeutic low molecular weight heparin (dalteparin) or unfractionated heparin. Clin Lab Haematol 1999;21:55–60.

106.

Moliterno

Hermiller

Kereiakes

. A novel point-of-care enoxaparin monitor for use during percutaneous coronary intervention. Results of the Evaluating Enoxaparin Clotting Times (ELECT) Study. J Am Coll Cardiol 2003;42:1132–9.

107.

Saw

Kereiakes

Mahaffey

. Evaluation of a novel point-of-care enoxaparin monitor with central laboratory anti-Xa levels. Thromb Res 2003;112:301–6.

108.

Cavusoglu

Lakhani

Marmur

. The activated clotting time (ACT) can be used to monitor enoxaparin and dalteparin after intravenous administration. J Invasive Cardiol 2005;17:416–21.

109.

Phillips

Buchan

Newman

Rajan

Zia

. Low-molecular-weight heparin may alter point-of-care assay for international normalized ratio. Pharmacotherapy 2005;25:1341–7.

110.

Spinier

Wittkowsky

Nutescu

Smythe

. Anticoagulation monitoring part 2: unfractionated heparin and low-molecular-weight heparin. Ann Pharmacother 2005;39:1275–85. Epub 14 Jun 2005. DOI 10.1345/aph.1E524

111.

Spinier

Nutescu

Smythe

Wittkowsky

. Anticoagulation monitoring part 1: warfarin and parenteral direct thrombin inhibitors. Ann Pharmacother 2005;39:1049–55. Epub 26 Apr 2005. DOI 10.1345/aph.1E118

112.

Cambus

Saivin

Heilmann

Caplain

Boneu

Houin

. The pharmacodynamics of tinzaparin in healthy volunteers. Br J Haematol 2002;116:649–52.

113.

Harenberg

Giese

Dempfle

Stehle

Heene

. Biological activity and safety of the subcutaneous administration of high doses of low molecular weight heparin for 8 days in human volunteers. Thromb Haemost 1989;61:357–62.

114.

Collignon

Frydman

Caplain

. Comparison of the pharmacokinetic profiles of three low molecular mass heparins—dalteparin, enoxaparin and nadroparin—administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism), Thromb Haemost 1995; 73: 630–40.

115.

Eriksson

Söderberg

Widlund

Wandeli

Tengborn

Risberg

. A comparative study of three low-molecular weight heparins (LMWH) and unfractionated heparin (UH) in healthy volunteers. Thromb Haemost 1995;73:398–401.

116.

Boneu

Nguyen

Cambus

J-P

. Difficultés et pièges de la surveillance des traitements par l'héparine. Sang Thrombose Vaisseaux 2003;15:131–4.

117.

Monagle

Michelson

Bovill

Andrew

. Antithrombotic therapy in children. Chest 2001;119(suppl 1):344S–70S.